A
Alumis
Developing precision medicines for autoimmune diseases
About Alumis
Alumis is a healthcare startup that focuses on developing precision therapies for patients suffering from immune-mediated diseases. The company operates in the biotechnology and pharmaceutical market, specifically targeting the niche of immunologic diseases. Alumis' business model is centered around the development and commercialization of innovative therapies, which are designed to improve clinical outcomes for patients.
The company's approach is rooted in a deep understanding of immunologic diseases and is driven by the principle of delivering the right medicine to achieve the best clinical outcome. Alumis uses precision medicine, a method that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. This approach enables the company to select the right targets, molecules, indications, patients, endpoints, and potential combinations to optimize patient outcomes.
Alumis' revenue model is likely based on the sales of these developed therapies, either directly or through partnerships with other healthcare providers or pharmaceutical companies. The company may also generate income through licensing its technologies or through strategic partnerships.
In summary, Alumis is a biotech startup that uses precision medicine to develop therapies for immune-mediated diseases, aiming to improve patient outcomes through targeted treatment strategies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2024
- Employees
- 230
- Open positions
- None listed
- Dealroom signal
- 91.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Rumoured $1B, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Feb 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $169M | — | Deep Track Capital | ↗ |
| POST IPO EQUITYOther financing | Jan 2026 | $345M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $24M | 0% | −$638M | -2653.7% |
| 2025 | $24M | — | −$638M | -2653.7% |
| 2024 | $0 | — | −$292M | — |
| 2023 | $0 | — | −$157M | — |
| 2022 | $0 | — | −$114M | — |
Growth signals
Latest recorded traffic for Alumis is 13K monthly website visits, down 56.7% over the last three months. Alumis's team grew 0.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Foresite Capital
Matrix Capital Management
Series B and later11 investors entered at this stage
SR One
venBio Partners
Ally Bridge Group
Samsara BioCapital- NENextech
Omega Funds
Cormorant Asset Management
Lilly Asia Ventures
Piper Sandler
HBM Healthcare Investments
Deep Track Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alumis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alumis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.